Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2023 HR+/HER2- mBC
SABCS 2023 HR+/HER2- MBC
CKD4/6 Inhibitors Found to Be Less Effective in Patients with HR+/HER2- Metastatic Breast Cancer with Bone-Only Metastases
SABCS 2023 HR+/HER2- MBC
Retrospective study of patients with HR+/HER2− metastatic breast cancer with bone-only metastases and pre-clinical data finds CDK4/6 inhibitors not as effective as in patients with metastases to other body sites.
Read More ›
Action Plans and Educational Resources Found to Increase Oral Medication Compliance in Patients with Breast Cancer
SABCS 2023 HR+/HER2- MBC
The development of action plans by providers and use of educational sessions found to improve patient compliance with oral oncolytics for those with HR+/HER2− breast cancer.
Read More ›
Real-World Analysis Finds Shift in Clinician Preferences for CDK4/6 Inhibitors for Patients with HR+/HER2− Metastatic Breast Cancer
SABCS 2023 HR+/HER2- MBC
Real-world analysis finds a preference shift from palbociclib to ribociclib and no significant differences in time to next treatment or time to treatment discontinuation for patients with HR+/HER-metastatic breast cancer.
Read More ›
Elacestrant Conveys Improved PFS in Patients with ER+/HER2− Metastatic Breast Cancer with Prior CDK4/6 Inhibitors
SABCS 2023 HR+/HER2- MBC
Study finds that patients with ER+/HER2− metastatic breast cancer who have prior CDK4/6 inhibitor treatment have a greater PFS when treated with elacestrant compared to standard of care.
Read More ›
Barriers to Oncology-Related Information and Referrals Reported by Oncology Nurse Navigators
SABCS 2023 HR+/HER2- MBC
Oncology nurse navigators who work with younger patients with breast cancer and patients with metastatic breast cancer report barriers to services, information, and referrals.
Read More ›
Predictive Algorithm Demonstrates Association With Progression-Free and Overall Survival in Patients With Metastatic Breast Cancer
SABCS 2023 HR+/HER2- MBC
An algorithm of composite biomarkers and pathological variables is associated with predicting progression-free survival and overall survival in patients with HR+/HER2-metastatic breast cancer.
Read More ›
Peer Support Groups Impact Older Women Living with Metastatic Breast Cancer
SABCS 2023 HR+/HER2- MBC
Study finds older women with metastatic breast cancer in Nigeria benefit from belonging to a peer support group.
Read More ›
ESR1 Mutations in ER+ Breast Cancer Cells Found to Promote CDK4/6 Inhibitor Resistance
SABCS 2023 HR+/HER2- MBC
Recent study results find mutations in the ESR1 gene directly promote resistance to CDK4/6 inhibitors used alone or in combination with antiestrogens.
Read More ›
First-Line Treatment Differences Found in Black and Younger Patients with HR+/HER2– Metastatic Breast Cancer
SABCS 2023 HR+/HER2- MBC
Recent analysis finds that Black and younger patients with metastatic breast cancer are more likely to receive chemotherapy first-line and less likely to receive CDK4/6 inhibitors when receiving endocrine therapy.
Read More ›
Parenthood Impacts Treatment Decisions in Women With Metastatic Breast Cancer
SABCS 2023 HR+/HER2- MBC
Qualitative study finds the presence of children or grandchildren is a primary treatment decision factor for women with metastatic breast cancer.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us